Inquiry Basket
CAS No.: 1824663-83-3
Cat No.: BADC-01600
4.5 
Sirtratumab vedotin is an antibody-drug conjugate consisting of a SLITRK6-specific human antibody conjugated to MMAE via a protease-cleavable linker. Sirtratumab vedotin has the potential for the treatment of advanced urothelial cancer.
Structure of 1824663-83-3
* For research and manufacturing use only. We do not sell to patients.
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Popular Publications Citing BOC Sciences Products
| Catalog | Product Name | CAS | Inquiry |
|---|---|---|---|
| BADC-01614 | Glembatumumab vedotin | 1182215-65-1 | |
| BADC-01606 | Polatuzumab vedotin | 1313206-42-6 | |
| BADC-01596 | Enfortumab vedotin-ejfv | 1346452-25-2 | |
| BADC-01610 | Tisotumab vedotin | 1418731-10-8 | |
| BADC-01597 | Ladiratuzumab vedotin | 1629760-29-7 | |
| BADC-01605 | Telisotuzumab vedotin | 1714088-51-3 | |
| BADC-01604 | Disitamab vedotin | 2136633-23-1 | |
| BADC-00031 | Brentuximab vedotin | 914088-09-8 | |
| BADC-01613 | Zilovertamab vedotin |
Sirtratumab vedotin
Required fields are marked with *
Sirtratumab vedotin
Required fields are marked with *
Contact our experts today for pricing and comprehensive details on our ADC offerings.
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.
